Selective use of sorafenib in the treatment of thyroid cancer

References

• JemalABrayFCenterMMFerlayJWardEFormanDGlobal cancer statisticsCA Cancer J Clin2011612699021296855
   PubMed Web of Science ®Google Scholar
• HundahlSAFlemingIDFremgenAMMenckHRA National Cancer Data Base report on 53,856 cases of thyroid carcinoma treated in the U.S., 1985–1995Cancer19988312263826489874472
   PubMed Web of Science ®Google Scholar
• Eustatia-RuttenCFCorssmitEPBiermaszNRPereiraAMRomijnJASmitJWSurvival and death causes in differentiated thyroid carcinomaJ Clin Endocrinol Metab200691131331916263822
   PubMed Web of Science ®Google Scholar
• HaugenBRAlexanderEKBibleKC2015 American Thyroid Association Management Guidelines for adult patients with thyroid nodules and differentiated thyroid cancerThyroid201626113326462967
   PubMed Web of Science ®Google Scholar
• DuranteCHaddyNBaudinELong-term outcome of 444 patients with distant metastases from papillary and follicular thyroid carcinoma: benefits and limits of radioiodine therapyJ Clin Endocrinol Metab20069182892289916684830
   PubMed Web of Science ®Google Scholar
• HodakSPCartySERadioiodine-resistant differentiated thyroid cancer: hope for the futureOncology200923977577619777763
   PubMed Web of Science ®Google Scholar
• RobbinsRJWanQGrewalRKReal-time prognosis for metastatic thyroid carcinoma based on 2-[18F]fluoro-2-deoxyd-glucose-positron emission tomography scanningJ Clin Endocrinol Metab200691249850516303836
   PubMed Web of Science ®Google Scholar
• American Thyroid Association (ATA) Guidelines Taskforce on Thyroid Nodules and Differentiated Thyroid CancerCooperDSDohertyGMRevised American Thyroid Association Management Guidelines for patients with thyroid nodules and differentiated thyroid cancerThyroid200919111167121419860577
   PubMed Web of Science ®Google Scholar
• PitoiaFWardLWohllkNRecommendations of the Latin American Thyroid Society on diagnosis and management of differentiated thyroid cancerArq Bras Endocrinol Metabol200953788488719942992
   PubMedGoogle Scholar
• BroseMSSmitJCapdevilaJApproach to the patient with advanced differentiated thyroid cancerExpert Rev Anticancer Ther20121291137114723098114
   PubMed Web of Science ®Google Scholar
• SchlumbergerMBroseMEliseiRDefinition and management of radioactive iodine-refractory differentiated thyroid cancerLancet Diabetes Endocrinol20141327021570218
   Google Scholar
• PaciniFItoYLusterMPitoiaFRobinsonBWirthLRadioactive iodine-refractory differentiated thyroid cancer: unmet needs and future directionsExpert Rev Endocrinol Metab201275541554
   PubMedGoogle Scholar
• EisenhauerEATherassePBogaertsJNew response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)Eur J Cancer200945222824719097774
   PubMed Web of Science ®Google Scholar
• KimABalisFMWidemannBCSorafenib and sunitinibOncologist200914880080519648603
   PubMed Web of Science ®Google Scholar
• MarottaVGuerraASapioMRVitaleMRET/PTC rearrangement in benign and malignant thyroid diseases: a clinical standpointEur J Endocrinol2011165449950721750045
   PubMed Web of Science ®Google Scholar
• FaginJAChallenging dogma in thyroid cancer molecular genetics – role of RET/PTC and BRAF in tumor initiationJ Clin Endocrinol Metab20048994264426615356019
   PubMed Web of Science ®Google Scholar
• SantoroMMelilloRMFuscoARET/PTC activation in papillary thyroid carcinoma: European Journal of Endocrinology Prize LectureEur J Endocrinol2006155564565317062879
   PubMed Web of Science ®Google Scholar
• XingMBRAF mutation and thyroid cancer recurrenceJ Clin Oncol201533222482248326124474
   PubMed Web of Science ®Google Scholar
• MinolettiFButtiMGCoronelliSThe two genes generating RET/PTC3 are localized in chromosomal band 10q11.2Genes Chromosomes Cancer199411151577529046
   PubMed Web of Science ®Google Scholar
• SuarezHGdu VillardJASeverinoMPresence of mutations in all three ras genes in human thyroid tumorsOncogene1990545655702183158
   PubMed Web of Science ®Google Scholar
• Garcia-RostanGZhaoHCampRLRas mutations are associated with aggressive tumor phenotypes and poor prognosis in thyroid cancerJ Clin Oncol200321173226323512947056
   PubMed Web of Science ®Google Scholar
• EzzatSZhengLKolendaJSafarianAFreemanJLAsaSLPrevalence of activating ras mutations in morphologically characterized thyroid nodulesThyroid1996654094168936664
   PubMed Web of Science ®Google Scholar
• VaskoVVGaudartJAllasiaCThyroid follicular adenomas may display features of follicular carcinoma and follicular variant of papillary carcinomaEur J Endocrinol2004151677978615588246
   PubMed Web of Science ®Google Scholar
• SabraMMDominguezJMGrewalRKClinical outcomes and molecular profile of differentiated thyroid cancers with radioiodine-avid distant metastasesJ Clin Endocrinol Metab2013985E829E83623533233
   PubMed Web of Science ®Google Scholar
• HoALGrewalRKLeboeufRSelumetinib-enhanced radioiodine uptake in advanced thyroid cancerN Engl J Med2013368762363223406027
   PubMed Web of Science ®Google Scholar
• HowellGMHodakSPYipLRAS mutations in thyroid cancerOncologist201318892693223873720
   PubMed Web of Science ®Google Scholar
• KimuraETNikiforovaMNZhuZKnaufJANikiforovYEFaginJAHigh prevalence of BRAF mutations in thyroid cancer: genetic evidence for constitutive activation of the RET/PTC-RAS-BRAF signaling pathway in papillary thyroid carcinomaCancer Res20036371454145712670889
   PubMed Web of Science ®Google Scholar
• XingMBRAF mutation in thyroid cancerEndocr Relat Cancer200512224526215947100
   PubMed Web of Science ®Google Scholar
• XingMWestraWHTufanoRPBRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancerJ Clin Endocrinol Metab200590126373637916174717
   PubMed Web of Science ®Google Scholar
• XingMBRAF mutation in papillary thyroid cancer: pathogenic role, molecular bases, and clinical implicationsEndocr Rev200728774276217940185
   PubMed Web of Science ®Google Scholar
• O’NeillCJBullockMChouABRAF(V600E) mutation is associated with an increased risk of nodal recurrence requiring reoperative surgery in patients with papillary thyroid cancerSurgery201014861139114521134544
   PubMed Web of Science ®Google Scholar
• WangWZhaoWWangHPoorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinomaAnn Surg Oncol2012191313622033631
   PubMed Web of Science ®Google Scholar
• GrabellusFWormKSchmidKWSheuSYThe BRAF V600E mutation in papillary thyroid carcinoma is associated with glucose transporter 1 overexpressionThyroid201222437738222376167
   PubMed Web of Science ®Google Scholar
• JooJYParkJYYoonYHPrediction of occult central lymph node metastasis in papillary thyroid carcinoma by preoperative BRAF analysis using fine-needle aspiration biopsy: a prospective studyJ Clin Endocrinol Metab201297113996400322930785
   PubMed Web of Science ®Google Scholar
• XingMBRAFV600E mutation and papillary thyroid cancer: chicken or egg?J Clin Endocrinol Metab20129772295229822774213
   PubMed Web of Science ®Google Scholar
• GuerraASapioMRMarottaVThe primary occurrence of BRAF(V600E) is a rare clonal event in papillary thyroid carcinomaJ Clin Endocrinol Metab201297251752422170714
   PubMed Web of Science ®Google Scholar
• GuerraAFugazzolaLMarottaVA high percentage of BRAFV600E alleles in papillary thyroid carcinoma predicts a poorer outcomeJ Clin Endocrinol Metab20129772333234022508706
   PubMed Web of Science ®Google Scholar
• de BiaseDCesariVVisaniMHigh-sensitivity BRAF mutation analysis: BRAF V600E is acquired early during tumor development but is heterogeneously distributed in a subset of papillary thyroid carcinomasJ Clin Endocrinol Metab2014998E1530E153824780046
   PubMed Web of Science ®Google Scholar
• SajiMRingelMDThe PI3K-Akt-mTOR pathway in initiation and progression of thyroid tumorsMol Cell Endocrinol20103211202819897009
   PubMed Web of Science ®Google Scholar
• Ricarte-FilhoJCRyderMChitaleDAMutational profile of advanced primary and metastatic radioactive iodine-refractory thyroid cancers reveals distinct pathogenetic roles for BRAF, PIK3CA, and AKT1Cancer Res200969114885489319487299
   PubMed Web of Science ®Google Scholar
• LandaIGanlyIChanTAFrequent somatic TERT promoter mutations in thyroid cancer: higher prevalence in advanced forms of the diseaseJ Clin Endocrinol Metab2013989E1562E156623833040
   PubMed Web of Science ®Google Scholar
• LiuXQuSLiuRTERT promoter mutations and their association with BRAF V600E mutation and aggressive clinicopathological characteristics of thyroid cancerJ Clin Endocrinol Metab2014996E1130E113624617711
   PubMed Web of Science ®Google Scholar
• MalaguarneraRChenKYKimTYSwitch in signaling control of mTORC1 activity after oncoprotein expression in thyroid cancer cell linesJ Clin Endocrinol Metab20149910E1976E198725029414
   PubMed Web of Science ®Google Scholar
• BunoneGVigneriPMarianiLExpression of angiogenesis stimulators and inhibitors in human thyroid tumors and correlation with clinical pathological featuresAm J Pathol19991551967197610595926
   PubMed Web of Science ®Google Scholar
• EscudierBEisenTStadlerWMSorafenib for treatment of renal cell carcinoma: final efficacy and safety results of the phase III treatment approaches in renal cancer global evaluation trialJ Clin Oncol200927203312331819451442
   PubMed Web of Science ®Google Scholar
• LlovetJMRicciSMazzaferroVSHARP Investigators Study GroupSorafenib in advanced hepatocellular carcinomaN Engl J Med2008359437839018650514
   PubMed Web of Science ®Google Scholar
• BroseMSNuttingCMJarzabBDECISION investigatorsSorafenib in radioactive iodine-refractory, locally advanced or metastatic differentiated thyroid cancer: a randomised, double-blind, phase 3 trialLancet2014384994031932824768112
   PubMed Web of Science ®Google Scholar
• AdnaneLTrailPATaylorIWilhelmSMSorafenib (BAY 43-9006, Nexavar), a dual-action inhibitor that targets RAF/MEK/ERK pathway in tumor cells and tyrosine kinases VEGFR/PDGFR in tumor vasculatureMethods Enzymol200640759761216757355
   PubMed Web of Science ®Google Scholar
• WilhelmSMCarterCTangLBAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesisCancer Res200464197099710915466206
   PubMed Web of Science ®Google Scholar
• Bayer HealthCare Pharmaceuticals Inc [webpage on the Internet]Prescribing Information for Sorafenib (Nexavar)USABayer HealthCare Pharmaceuticals Inc2011 Available from: http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/021923s016lbl.pdfAccessed September 14, 2015
   Google Scholar
• European Medicines Agency [homepage on the internet]Nexavar (Sorafenib): Summary of Product CharacteristicsUnited KingdomEuropean Medicines Agency2014 Available from: http://www.ema.europa.euAccessed September 14, 2015
   Google Scholar
• StrumbergDRichlyHHilgerRAPhase I clinical and phar-macokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006 in patients with advanced refractory solid tumorsJ Clin Oncol200523596597215613696
   PubMed Web of Science ®Google Scholar
• FallahiPFerrariSMSantiniFSorafenib and thyroid cancerBioDrugs201327661562823818056
   PubMed Web of Science ®Google Scholar
• BastholtLBroseMSJarzabBPopulation PK modeling and exposure-response analyses of sorafenib in patients with radioactive iodine-refractory differentiated thyroid cancer (RAI-rDTC) in the phase III DECISION trialJ Clin Oncol201432suppl 56061
   Google Scholar
• KloosRMRKnoppMHeverhagenJSignificant clinical and biologic activity of RAF/VEGF-R kinase inhibitor BAY 43-9006 in patients with metastatic papillary thyroid carcinoma (PTC): updated results of a phase II studyJ Clin Oncol200624suppl 2885534
   Google Scholar
• Gupta-AbramsonVTroxelABNelloreAPhase II trial of sorafenib in advanced thyroid cancerJ Clin Oncol200826294714471918541894
   PubMed Web of Science ®Google Scholar
• KloosRTRingelMDKnoppMVPhase II trial of sorafenib in metastatic thyroid cancerJ Clin Oncol200927101675168419255327
   PubMed Web of Science ®Google Scholar
• BroseMSTroxelABRedlingerMEffect of BRAFV600E on response to sorafenib in advanced thyroid cancer patientsJ Clin Oncol200927suppl 156002
   Web of Science ®Google Scholar
• HoftijzerHHeemstraKAMorreauHBeneficial effects of sorafenib on tumor progression, but not on radioiodine uptake, in patients with differentiated thyroid carcinomaEur J Endocrinol2009161692393119773371
   PubMed Web of Science ®Google Scholar
• CabanillasMEWaguespackSGBronsteinYTreatment with tyrosine kinase inhibitors for patients with differentiated thyroid cancer: the M.D. Anderson experienceJ Clin Endocrinol Metab20109562588259520392874
   PubMed Web of Science ®Google Scholar
• KeefeSMTroxelABRheeSPhase II trial of sorafenib in patients with advanced thyroid cancerJ Clin Oncol201129suppl 155562
   Google Scholar
• MarottaVRamandoVCameraLSorafenib in advanced iodine-refractory differentiated thyroid cancer: efficacy, safety and exploratory analysis of role of serum thyroglobulin and FDG-PETClin Endocrinol (Oxf)201278576076723009688
   PubMed Web of Science ®Google Scholar
• SchneiderTCAbdulrahmanRMCorssmitEPMorreauHSmitJWKapiteijnELong-term analysis of the efficacy and tolerability of sorafenib in advanced radio-iodine refractory differentiated thyroid carcinoma: final results of a phase II trialEur J Endocrinol2012167564365022918300
   PubMed Web of Science ®Google Scholar
• LamETRingelMDKloosRTPhase II clinical trial of sorafenib in metastatic medullary thyroid cancerJ Clin Oncol201028142323233020368568
   PubMed Web of Science ®Google Scholar
• AhmedMBarbachanoYRiddellAAnalysis of the efficacy and toxicity of sorafenib in thyroid cancer: a phase II study in a UK based populationEur J Endocrinol2011165231532221566072
   PubMed Web of Science ®Google Scholar
• CapdevilaJIglesiasLHalperinISorafenib in metastatic thyroid cancerEndocr Relat Cancer201219220921622285864
   PubMed Web of Science ®Google Scholar
• DaduRWaguespackSGShermanSIEfficacy and tolerability of different starting doses of sorafenib in patients with differentiated thyroid cancerOncologist201419547748224733667
   PubMed Web of Science ®Google Scholar
• ChenLShenYLuoQYuYLuHZhuRResponse to sorafenib at a low dose in patients with radioiodine-refractory pulmonary metastases from papillary thyroid carcinomaThyroid201121211912421186953
   PubMed Web of Science ®Google Scholar
• ShenCTQiuZLLuoQYSorafenib in the treatment of radioiodine-refractory differentiated thyroid cancer: a meta-analysisEndocr Relat Cancer201421225326124302666
   PubMed Web of Science ®Google Scholar
• Klein HesselinkENSteenvoordenDKapiteijnETherapy of endocrine disease: response and toxicity of small-molecule tyrosine kinase inhibitors in patients with thyroid carcinoma: a systematic review and meta-analysisEur J Endocrinol20151725R215R22525572389
   PubMed Web of Science ®Google Scholar
• MassicotteMHBrassardMClaude-DesrochesMTyrosine kinase inhibitor treatments in patients with metastatic thyroid carcinomas: a retrospective study of the TUTHYREF networkEur J Endocrinol2014170457558224424318
   PubMed Web of Science ®Google Scholar
• GalloMMichelonFCastiglioneASorafenib treatment of radioiodine-refractory advanced thyroid cancer in daily clinical practice: a cohort study from a single centerEndocrine201549372673425414068
   PubMed Web of Science ®Google Scholar
• PitoiaFResponse to sorafenib treatment in advanced metastatic thyroid cancerArq Bras Endocrinol Metabol2014581374124728162
   PubMedGoogle Scholar
• Clinicaltrials.gov [webpage on the Internet]Nexavar® versus Placebo in Locally Advanced/Metastatic RAI-Refractory Differentiated Thyroid CancerUSANational Institutes of Health2015 Available from: https://clinicaltrials.gov/ct2/show/NCT00984282?term=NCT00984282&rank=1Accessed October 14, 2015
   Google Scholar
• TuttleRMHaddadRIBallDWThyroid carcinoma, version 2.2014J Natl Compr Canc Netw201412121671168025505208
   PubMed Web of Science ®Google Scholar
• CabanillasMEKurzrockRShermanSIPhase I trial of combination sorafenib and tipifarnib: the experience of advanced differentiated thyroid cancer (DTC) and medullary thyroid cancer (MTC)J Clin Oncol201028suppl 155586
   Web of Science ®Google Scholar
• HongDSCabanillasMEWhelerJInhibition of the Ras/Raf/MEK/ERK and RET kinase pathways with the combination of the multikinase inhibitor sorafenib and the farnesyltransferase inhibitor tipifarnib in medullary and differentiated thyroid malignanciesJ Clin Endocrinol Metab2011964997100521289252
   PubMed Web of Science ®Google Scholar
• ShermanEJHoALFuryMGA phase II study of temsirolimus/sorafenib in patients with radioactive iodine (RAI)-refractory thyroid carcinomaJ Clin Oncol201230suppl 155514
   Web of Science ®Google Scholar
• ShermanEJHoALFuryMGPhase II study of everolimus and sorafenib for the treatment of metastatic thyroid cancerJ Clin Oncol201331suppl6024
   Google Scholar
• BroseMSTroxelABYarchoanMA phase II study of everolimus (E) and sorafenib (S) in patients (PTS) with metastatic differentiated thyroid cancer who have progressed on sorafenib aloneJ Clin Oncol201533suppl6072
   Google Scholar
• US Dept of Health and Human Services, National Institutes of Health, National Cancer Institute [webpage on the Internet]Common Terminology Criteria for Adverse Events v4.0 (CTCAE). US Dept of Health and Human Services, National Institutes of Health, National Cancer Institute2006 Available from: http://ctep.cancer.gov/protocolDevelopment/electronic_applications/ctc.htmAccessed September 25, 2015
   Google Scholar
• SchutzFAJeYRichardsCJChoueiriTKMeta-analysis of random-ized controlled trials for the incidence and risk of treatment-related mortality in patients with cancer treated with vascular endothelial growth factor tyrosine kinase inhibitorsJ Clin Oncol201230887187722312105
   PubMed Web of Science ®Google Scholar
• WordenFFassnachtMShiYSafety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancerEndocr Relat Cancer201522687788726370187
   PubMed Web of Science ®Google Scholar
• LeeWJLeeJLChangSECutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinibBr J Dermatol200916151045105119558553
   PubMed Web of Science ®Google Scholar
• FlahertyKTBroseMSSorafenib-related hand-foot skin reaction improves, not worsens, with continued treatmentClin Cancer Res20091524774920008857
   PubMed Web of Science ®Google Scholar
• BroseMSFrenetteCTKeefeSMSteinSMManagement of sorafenib-related adverse events: a clinician’s perspectiveSemin Oncol201441suppl 2S1S1624576654
   PubMedGoogle Scholar
• RobinsonESKhankinEVKarumanchiSAHumphreysBDHypertension induced by vascular endothelial growth factor signaling pathway inhibition: mechanisms and potential use as a biomarkerSemin Nephrol201030659160121146124
   PubMed Web of Science ®Google Scholar
• KambaTMcDonaldDMMechanisms of adverse effects of anti-VEGF therapy for cancerBr J Cancer200796121788179517519900
   PubMed Web of Science ®Google Scholar
• ZhangZFWangTLiuLHGuoHQRisks of proteinuria associated with vascular endothelial growth factor receptor tyrosine kinase inhibitors in cancer patients: a systematic review and meta-analysisPLoS One201493e9013524621598
   PubMed Web of Science ®Google Scholar
• QiWShenZTangLYaoYCongestive heart failure risk in cancer patients treated with VEGFR-MKIs: a systematic review and meta-analysis of 36 clinical trialsBr J Clin Pharmacol201478474876224661224
   PubMed Web of Science ®Google Scholar
• BraunDKimTDle CoutrePKöhrleJHershmanJMSchweizerUTyrosine kinase inhibitors noncompetitively inhibit MCT8-mediated iodothyronine transportJ Clin Endocrinol Metab2012971E100E10522031512
   PubMed Web of Science ®Google Scholar
• AbdulrahmanRMVerloopHHoftijzerHSorafenib-induced hypothyroidism is associated with increased type 3 deiodinationJ Clin Endocrinol Metab20109583758376220484486
   PubMed Web of Science ®Google Scholar
• VerloopHSmitJWDekkersOMSorafenib therapy decreases the clearance of thyrotropinEur J Endocrinol2013168216316723125304
   PubMed Web of Science ®Google Scholar
• IllouzFLaboureau-SoaresSDuboisSRohmerVRodienPTyrosine kinase inhibitors and modifications of thyroid function tests: a reviewEur J Endocrinol2009160333133619103722
   PubMed Web of Science ®Google Scholar
• SchutzFAJeYChoueiriTKHematologic toxicities in cancer patients treated with the multi-tyrosine kinase sorafenib: a meta-analysis of clinical trialsCrit Rev Oncol Hematol201180229130021339073
   PubMed Web of Science ®Google Scholar
• PitoiaFAbelleiraEJerkovichFUrciuoliCCrossGPartial response to sorafenib treatment associated with transient grade 3 thrombocytope-nia in a patient with locally advanced thyroid cancerArch Endocrinol Metab201559434735026331323
   PubMed Web of Science ®Google Scholar
• RothenbergSMMcFaddenDGPalmerELDanielsGHWirthLJRedifferentiation of iodine-refractory BRAF V600E-mutant metastatic papillary thyroid cancer with dabrafenibClin Cancer Res20152151028103525549723
   PubMed Web of Science ®Google Scholar